Where Will RocketLab Stock Be In 5 Years?
Rocket Lab (NASDAQ: RKLB) closed recently at around $30 per share,…
Sell
32
RNAC Quote, Financials, Valuation and Earnings
Last price:
$9.83
Seasonality move
:
3.36%
Day range:
$9.63 - $10.11
52-week range:
$8.46 - $29.65
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.49x
P/B ratio:
568.21x
Volume:
79.8K
Avg. volume:
70.1K
1-year change:
-57.36%
Market cap:
$253.3M
Revenue:
$38.9M
EPS (TTM):
-$1.15
Analysts' Opinion
-
Consensus RatingCartesian Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $36.17, Cartesian Therapeutics has an estimated upside of 270.56% from its current price of $9.76.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 100% downside risk from its current price of $9.76.
Fair Value
-
According to the consensus of 6 analysts, Cartesian Therapeutics has 270.56% upside to fair value with a price target of $36.17 per share.
RNAC vs. S&P 500
-
Over the past 5 trading days, Cartesian Therapeutics has underperformed the S&P 500 by -4.54% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cartesian Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cartesian Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Cartesian Therapeutics reported revenues of $1.1M.
Earnings Growth
-
Cartesian Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Cartesian Therapeutics reported earnings per share of -$0.68.
Enterprise value:
72.9M
EV / Invested capital:
-3.34x
Price / LTM sales:
6.49x
EV / EBIT:
--
EV / Revenue:
2.13x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-1.80x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-9.71%
Net Income Margin (TTM):
-112.11%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-1989.91%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $82.7M | $25.9M | $34.2M | $5.8M | $1.1M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$14.6M | -$80.7M | -$44.9M | -$13.3M | -$21.9M | |
| EBITDA | -$11.4M | -$227.6M | -$40.1M | -$13.2M | -$20.7M | |
| Diluted EPS | -$5.44 | -$56.03 | -$1.15 | -$10.50 | -$0.68 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $163.1M | $130M | $138.4M | $111.1M | $185.1M | |
| Total Assets | $176.7M | $145.7M | $155.7M | $325.2M | $409.1M | |
| Current Liabilities | $84.6M | $39.2M | $26.5M | $36.7M | $15M | |
| Total Liabilities | $196.3M | $89.9M | $81.1M | $442M | $430.9M | |
| Total Equity | -$19.6M | $55.8M | $74.6M | -$116.8M | -$21.8M | |
| Total Debt | $25M | $25.7M | $26.4M | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$28.5M | -$58.3M | -$30.9M | -$15.9M | -$23.1M | |
| Cash From Investing | $3.6M | $5.9M | -$9.2M | -$602K | -$1.1M | |
| Cash From Financing | $37.6M | $29.7M | $117.4M | $43M | -$8M | |
| Free Cash Flow | -$29.4M | -$59M | -$40.4M | -$16.5M | -$24.2M | |
RNAC
Sector
Market Cap
$253.3M
$32.8M
Price % of 52-Week High
32.92%
46.28%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-57.36%
-35.38%
Beta (5-Year)
0.455
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$10.21
200-day SMA
Sell
Level
$16.37
Bollinger Bands (100)
Sell
Level
9.98 - 17.54
Chaikin Money Flow
Sell
Level
-9.2M
20-day SMA
Sell
Level
$9.90
Relative Strength Index (RSI14)
Sell
Level
44.69
ADX Line
Sell
Level
12.8
Williams %R
Neutral
Level
-69.6356
50-day SMA
Sell
Level
$10.59
MACD (12, 26)
Sell
Level
-0.16
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Sell
Level
-1.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.562)
Sell
CA Score
(Annual)
Level (-6.433)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (5.2508)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
Stock Forecast FAQ
In the current month, RNAC has received 4 Buy ratings 2 Hold ratings, and 0 Sell ratings. The RNAC average analyst price target in the past 3 months is $36.17.
-
Where Will Cartesian Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cartesian Therapeutics share price will rise to $36.17 per share over the next 12 months.
-
What Do Analysts Say About Cartesian Therapeutics?
Analysts are divided on their view about Cartesian Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cartesian Therapeutics is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is Cartesian Therapeutics's Price Target?
The price target for Cartesian Therapeutics over the next 1-year time period is forecast to be $36.17 according to 6 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is RNAC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cartesian Therapeutics is a Buy. 4 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RNAC?
You can purchase shares of Cartesian Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cartesian Therapeutics shares.
-
What Is The Cartesian Therapeutics Share Price Today?
Cartesian Therapeutics was last trading at $9.83 per share. This represents the most recent stock quote for Cartesian Therapeutics. Yesterday, Cartesian Therapeutics closed at $9.76 per share.
-
How To Buy Cartesian Therapeutics Stock Online?
In order to purchase Cartesian Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is MO dividend Worth It?
Altria Group (NYSE: MO) is paying investors $1.02 a share…
How High Will Take-Two Stock Go?
Take-Two Interactive (NASDAQ:TTWO) is the video game development company behind…
Stock Ideas
Buy
64
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
83
GMS alert for Jun 23
GMS [GMS] is down 0.58% over the past day.
Buy
54
SMLR alert for Jun 23
Semler Scientific [SMLR] is up 1.66% over the past day.
Buy
57
GXO alert for Jun 23
GXO Logistics [GXO] is up 0.23% over the past day.
